


CLAIMS

What is claimed is:

1. A method of ameliorating or treating a viral infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of
- 5 Formula (A), or a pharmaceutically acceptable salt and/or a stereoisomer thereof, wherein Formula (A) is:



wherein:

- X is NR²;
- 10 Z is O, S or NH;
- R¹ is selected from the group consisting of H, C₁-C₆alkyl, phenyl, -C(O)R³¹, -C(S)R³¹, -C(NH)R³¹ and -C(O)OR³², wherein C₁-C₆ alkyl is optionally substituted by one, two or three substituents each independently selected from -C(O)NR^aR^b, -NR^aR^b, hydroxyl, S(O)_w-C₁-C₃alkyl, SH, phenyl and halogen; and phenyl, independently for each
- 15 occurrence, is optionally substituted by one, two or three substituents each independently selected from hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃;
- R² is selected from the group consisting of -C(O)R³¹, -C(S)R³¹, -C(NH)R³¹ and -C(O)OR³²;
- 20 R³ is selected from the group consisting of H, C₁-C₆alkyl, phenyl, -C(O)R³¹, -C(S)R³¹, -C(NH)R³¹ and -C(O)OR³², wherein C₁-C₆ alkyl is optionally substituted by one, two or three substituents each independently selected from -C(O)NR^aR^b, -NR^aR^b, hydroxyl, S(O)_w-C₁-C₃alkyl, SH, phenyl and halogen; and phenyl, independently for each occurrence, is optionally substituted by one, two or three substituents each

independently selected from hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃;

R³¹ is C₁-C₆alkyl, wherein C₁-C₆ alkyl is substituted by one, two or three substituents each independently selected from hydroxyl, S(O)₂-C₁-C₃alkyl, halogen and -O-P(O)(R⁴¹R⁴²);

R³² is C₁-C₆alkyl;

R⁴¹ is selected from the group consisting of C₁-C₆alkyl, -C₃-C₆cycloalkyl, and -OR⁴³, wherein R⁴³ is selected from the group consisting of H, C₁-C₆alkyl, -C₃-C₆cycloalkyl, phenyl and naphthyl;

R⁴² is selected from the group consisting of -NH₂, -NH(C₁-C₆alkyl), and -N(C₁-C₆alkyl)₂, wherein the C₁-C₆alkyl is optionally substituted by one, two or three substituents each independently selected from oxo, hydroxyl, halogen, C₃-C₆cycloalkyl, C₁-C₆alkoxy, -C(O)-(C₁-C₆ alkyl), and -C(O)-O(C₁-C₆alkyl);

R⁵ is independently selected for each occurrence from the group consisting of H, C₁-C₆alkyl, -C₁-C₃alkoxy, -S(O)_w-C₁-C₃alkyl, -NR^aR^b, cyano and halogen;

R⁷ is independently selected for each occurrence from the group consisting of H, C₁-C₆alkyl, phenyl and halogen;


R^a and R^b are each independently for each occurrence selected from the group consisting of H, C₁-C₃alkyl, and phenyl, or R^a and R^b taken together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring;

p is 2;

n is, for each occurrence, 1; and

w is independently, for each occurrence, 0, 1 or 2.

2. A method of ameliorating or treating a viral infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (A), or a pharmaceutically acceptable salt and/or a stereoisomer thereof, wherein Formula (A) is:



wherein:

X is O or NR²;

Z is O, S or NH;

5 R¹ is selected from the group consisting of H, C₁-C₆alkyl, phenyl, -C(O)R³¹, -C(S)R³¹, -C(NH)R³¹ and -C(O)OR³², wherein C₁-C₆ alkyl is optionally substituted by one, two or three substituents each independently selected from -C(O)NR^aR^b, -NR^aR^b, hydroxyl, S(O)_w-C₁-C₃alkyl, SH, phenyl and halogen; and phenyl, independently for each
10 independently selected from hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃;

R² is selected from the group consisting of H, C₁-C₆alkyl, phenyl, -C(O)R³¹, -C(S)R³¹, -C(NH)R³¹ and -C(O)OR³², wherein C₁-C₆ alkyl is optionally substituted by one, two or three substituents each independently selected from -C(O)NR^aR^b, -NR^aR^b, hydroxyl,
15 S(O)_w-C₁-C₃alkyl, SH, phenyl and halogen; and phenyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃;

R³ is selected from the group consisting of H, C₁-C₆alkyl, phenyl, -C(O)R³¹, -C(S)R³¹,
20 -C(NH)R³¹ and -C(O)OR³², wherein C₁-C₆ alkyl is optionally substituted by one, two or three substituents each independently selected from -C(O)NR^aR^b, -NR^aR^b, hydroxyl, S(O)_w-C₁-C₃alkyl, SH, phenyl and halogen; and phenyl, independently for each occurrence, is optionally substituted by one, two or three substituents each
25 independently selected from hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃;

R^{31} and R^{32} are each independently selected from the group consisting of H, C₁-C₆alkyl, -C₃-C₆cycloalkyl, and phenyl, wherein C₁-C₆ alkyl is optionally substituted by one, two or three substituents each independently selected from -C(O)NR^aR^b, -NR^aR^b, hydroxyl, S(O)_w-C₁-C₃alkyl, SH, phenyl, halogen and -O-P(O)(R⁴¹R⁴²); and phenyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃;

R^{41} is selected from the group consisting of C₁-C₆alkyl, -C₃-C₆cycloalkyl, and -OR⁴³, wherein R^{43} is selected from the group consisting of H, C₁-C₆alkyl, -C₃-C₆cycloalkyl, phenyl, and naphthyl;

R^{42} is selected from the group consisting of -NH₂, -NH(C₁-C₆alkyl), and -N(C₁-C₆alkyl)₂, wherein the C₁-C₆alkyl is optionally substituted by one, two or three substituents each independently selected from oxo, hydroxyl, halogen, C₃-C₆cycloalkyl, C₁-C₆alkoxy, -C(O)-(C₁-C₆ alkyl), and -C(O)-O(C₁-C₆alkyl);

R^5 is independently selected for each occurrence from the group consisting of H, C₁-C₆alkyl, -C₁-C₃alkoxy, -S(O)_w-C₁-C₃alkyl, -NR^aR^b, cyano, and halogen;

R^7 is independently selected for each occurrence from the group consisting of H, C₁-C₆alkyl, phenyl, and halogen;

R^a and R^b are each independently for each occurrence selected from the group consisting of H, C₁-C₃alkyl, and phenyl, or R^a and R^b taken together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring;


p is 1 or 2;

n is independently, for each occurrence, 0, 1 or 2; and

w is independently, for each occurrence, 0, 1 or 2.


3. The method of claim 1 or 2, wherein for Formula (A), R^5 , at each occurrence, is H.
4. The method of any one of claims 1-3, wherein for Formula (A), R^7 , at each occurrence, is H.
5. The method of any one of claims 1-4, wherein for Formula (A), at least one of R^1 , R^2 and R^3 , independently is -C(O)(C₁-C₆alkyl)X', wherein X' is a halogen.

6. The method of any one of claims 1-5, wherein for Formula (A), Z is O.
7. The method of claim 5, wherein for Formula (A), X' is Br, Cl, F, or I.
8. The method of any one of claims 1-4, wherein for Formula (A), at least one of R¹, R² and R³, independently is -C(O)(C₁-C₆alkyl)X', wherein X' is -O-P(O)(R⁴¹R⁴²), wherein R⁴¹ is
 5 selected from -O(C₁-C₆alkyl) and -O-phenyl, and R⁴² is -NH(C₁-C₆alkyl) optionally substituted by -C(O)-O(C₁-C₆alkyl).
9. The method of claim 8, wherein for Formula (A), Z is O.
10. The method of claim 8 or 9, wherein for Formula (A), X' is selected from the group consisting of:




11. The method of claim 2, wherein for Formula (A), n, for each occurrence is 1.
12. The method of claim 2, wherein for Formula (A), p is 1.
13. The method of any one of claims 1-12, wherein for Formula (A), R¹ is H.
14. The method of any one of claims 1-12, wherein for Formula (A), R¹ is -C₁alkyl-phenyl, wherein the phenyl may optionally be substituted by one, two or three halogens.
15. The method of claim 2, wherein for Formula (A), X is NR².

16. The method of any one of claims 1-7, 11, 12 and 15, wherein for Formula (A), R^2 is $-C(O)(C_1-C_6\text{alkyl})X'$, wherein X' is a halogen.
17. The method of any one of claims 1-7, 11, 12 and 15, wherein for Formula (A), R^2 is $-C(O)(CH_2)X'$, wherein X' is a halogen.
18. The method of claim 16 or 17, wherein X' is Br, Cl, F, or I.
19. The method of any one of claims 1-18, wherein for Formula (A), R^3 is $C_1-C_2\text{alkyl}$, optionally substituted by one or two substituents each independently selected from phenyl and halogen; and phenyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from hydroxyl, halogen, $-C(O)-C_1-C_3\text{alkyl}$, methyl, and CF_3 .
20. The method of any one of claims 1-18, wherein for Formula (A), R^3 is $-CH_2\text{-phenyl}$, wherein phenyl is optionally substituted by one, two or three substituents each independently selected from hydroxyl, halogen, $-C(O)-C_1-C_3\text{alkyl}$, methyl, and CF_3 .
21. The method of any one of claims 1-18, wherein for Formula (A), R^3 is H.
22. The method of claim 1, wherein Formula (A) is:




wherein X' is Br, Cl, or F.

23. The method of claim 1, wherein Formula (A) is:




wherein X' is I or $-O-P(O)(R^{41}R^{42})$, wherein R^{41} is selected from the group consisting of C_1 - C_6 alkyl, $-C_3$ - C_6 cycloalkyl, and $-OR^{43}$, wherein R^{43} is selected from the group consisting of H, C_1 - C_6 alkyl, $-C_3$ - C_6 cycloalkyl, phenyl and naphthyl; and R^{42} is selected from the group consisting of $-NH_2$, $-NH(C_1-C_6alkyl)$, and $-N(C_1-C_6alkyl)_2$, wherein the C_1 - C_6 alkyl is optionally substituted by one, two or three substituents each independently selected from oxo, hydroxyl, halogen, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, $-C(O)-(C_1-C_6alkyl)$, and $-C(O)-O(C_1-C_6alkyl)$.

24. The method of claim 23, wherein X' is selected from the group consisting of



25. The method of claim 1, wherein for Formula (A), the compound has the Formula (A-I):




wherein:

X' is a halogen; and

one, two or three of R^{1A} , R^{1B} , R^{1C} , R^{1D} , and R^{1E} are optionally each independently selected from the group consisting of hydroxyl, halogen, $-C(O)-O-C_1-C_3$ alkyl, $-C(O)-C_1-C_3$ alkyl, methyl, and CF_3 .

26. The method of claim 25, wherein for Formula (A-I), the compound is selected from the group consisting of a compound having Formula (A-II); a compound having Formula (A-III); and a compound having Formula (A-IV), wherein:


Formula (A-II) is:



wherein:


- 10 X' is a halogen; and
 R^{1A} and R^{1E} are optionally each independently selected from the group consisting of hydroxyl, halogen, $-C(O)-O-C_1-C_3$ alkyl, $-C(O)-C_1-C_3$ alkyl, methyl, and CF_3 ;

Formula (A-III) is:



- 15 wherein:
 X' is a halogen; and
 R^{1B} and R^{1D} are optionally each independently selected from the group consisting of hydroxyl, halogen, $-C(O)-O-C_1-C_3$ alkyl, $-C(O)-C_1-C_3$ alkyl, methyl, and CF_3 ; and

Formula (A-IV) is:




wherein:

X' is a halogen; and

R^{1C} is optionally selected from the group consisting of hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃.

27. The method of claim 25, wherein for Formula (A-I), the compound is selected from the group consisting of a compound having Formula (A-V); and a compound having Formula (A-VI), wherein:

Formula (A-V) is:




wherein:

X' is a halogen; and

R^{1A}, R^{1C}, and R^{1E} are optionally each independently selected from the group consisting of hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃; and

Formula (A-VI) is:




wherein:

X' is a halogen; and

R^{1B}, R^{1C}, and R^{1D} are optionally each independently selected from the group consisting of hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃.

28. The method of claim 1, wherein for Formula (A), the compound has the Formula (A-I):




wherein:

X' is -O-P(O)(R⁴¹R⁴²), wherein R⁴¹ is selected from the group consisting of C₁-C₆alkyl, -C₃-C₆cycloalkyl, and -OR⁴³, wherein R⁴³ is selected from the group consisting of H, C₁-C₆alkyl, -C₃-C₆cycloalkyl, phenyl and naphthyl; and R⁴² is selected from the group consisting of -NH₂, -NH(C₁-C₆alkyl), and -N(C₁-C₆alkyl)₂, wherein the alkyl is optionally substituted by one, two or three substituents each independently selected from oxo, hydroxyl, halogen, C₃-C₆cycloalkyl, C₁-C₆alkoxy, -C(O)-(C₁-C₆ alkyl), and -C(O)-O(C₁-C₆alkyl); and one, two or three of R^{1A}, R^{1B}, R^{1C}, R^{1D}, and R^{1E} are optionally each independently selected from the group consisting of H, hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃.

29. The method of claim 28, wherein for Formula (A-I), the compound is selected from the group consisting of a compound having Formula (A-II); a compound having Formula (A-III); and a compound having Formula (A-IV), wherein:

Formula (A-II) is:




wherein:

X' is -O-P(O)(R⁴¹R⁴²), wherein R⁴¹ is selected from the group consisting of C₁-C₆alkyl, -C₃-C₆cycloalkyl, and -OR⁴³, wherein R⁴³ is selected from the group consisting of H, C₁-C₆alkyl, -C₃-C₆cycloalkyl, phenyl and naphthyl; and R⁴² is selected from the group consisting of -NH₂, -NH(C₁-C₆alkyl), and -N(C₁-C₆alkyl)₂, wherein the alkyl is optionally substituted by one, two or three substituents each independently selected from oxo, hydroxyl, halogen, C₃-C₆cycloalkyl, C₁-C₆alkoxy, -C(O)-(C₁-C₆ alkyl), and -C(O)-O(C₁-C₆alkyl); and

R^{1A} and R^{1E} are optionally each independently selected from the group consisting of hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃;

Formula (A-III) is:




wherein:

X' is -O-P(O)(R⁴¹R⁴²), wherein R⁴¹ is selected from the group consisting of C₁-C₆alkyl, -C₃-C₆cycloalkyl, and -OR⁴³, wherein R⁴³ is selected from the group consisting of H, C₁-C₆alkyl, -C₃-C₆cycloalkyl, phenyl and naphthyl; and R⁴² is selected from the group

consisting of $-\text{NH}_2$, $-\text{NH}(\text{C}_1\text{-C}_6\text{alkyl})$, and $-\text{N}(\text{C}_1\text{-C}_6\text{alkyl})_2$, wherein the alkyl is optionally substituted by one, two or three substituents each independently selected from oxo, hydroxyl, halogen, $\text{C}_3\text{-C}_6\text{cycloalkyl}$, $\text{C}_1\text{-C}_6\text{alkoxy}$, $-\text{C}(\text{O})-(\text{C}_1\text{-C}_6\text{ alkyl})$, and $-\text{C}(\text{O})-\text{O}(\text{C}_1\text{-C}_6\text{alkyl})$; and

5 $\text{R}^{1\text{B}}$ and $\text{R}^{1\text{D}}$ are optionally each independently selected from the group consisting of hydroxyl, halogen, $-\text{C}(\text{O})-\text{O}-\text{C}_1\text{-C}_3\text{alkyl}$, $-\text{C}(\text{O})-\text{C}_1\text{-C}_3\text{alkyl}$, methyl, and CF_3 ; and

Formula (A-IV) is:



wherein:

10 X' is $-\text{O}-\text{P}(\text{O})(\text{R}^{41}\text{R}^{42})$, wherein R^{41} is selected from the group consisting of $\text{C}_1\text{-C}_6\text{alkyl}$, $-\text{C}_3\text{-C}_6\text{cycloalkyl}$, and $-\text{OR}^{43}$, wherein R^{43} is selected from the group consisting of H, $\text{C}_1\text{-C}_6\text{alkyl}$, $-\text{C}_3\text{-C}_6\text{cycloalkyl}$, phenyl and naphthyl; and R^{42} is selected from the group consisting of $-\text{NH}_2$, $-\text{NH}(\text{C}_1\text{-C}_6\text{alkyl})$, and $-\text{N}(\text{C}_1\text{-C}_6\text{alkyl})_2$, wherein the alkyl is optionally substituted by one, two or three substituents each independently selected


15 from oxo, hydroxyl, halogen, $\text{C}_3\text{-C}_6\text{cycloalkyl}$, $\text{C}_1\text{-C}_6\text{alkoxy}$, $-\text{C}(\text{O})-(\text{C}_1\text{-C}_6\text{ alkyl})$, and $-\text{C}(\text{O})-\text{O}(\text{C}_1\text{-C}_6\text{alkyl})$; and

$\text{R}^{1\text{C}}$ is optionally selected from the group consisting of hydroxyl, halogen, $-\text{C}(\text{O})-\text{O}-\text{C}_1\text{-C}_3\text{alkyl}$, $-\text{C}(\text{O})-\text{C}_1\text{-C}_3\text{alkyl}$, methyl, and CF_3 .

30. The method of claim 28, wherein for Formula (A-I), the compound is selected from the

20 group consisting of a compound having Formula (A-V); and a compound having Formula (A-VI), wherein:

Formula (A-V) is:




wherein:

5 X' is $-O-P(O)(R^{41}R^{42})$, wherein R^{41} is selected from the group consisting of C_1 - C_6 alkyl, $-C_3$ - C_6 cycloalkyl, and $-OR^{43}$, wherein R^{43} is selected from the group consisting of H, C_1 - C_6 alkyl, $-C_3$ - C_6 cycloalkyl, phenyl and naphthyl; and R^{42} is selected from the group consisting of $-NH_2$, $-NH(C_1-C_6alkyl)$, and $-N(C_1-C_6alkyl)_2$, wherein the alkyl is optionally substituted by one, two or three substituents each independently selected from oxo, hydroxyl, halogen, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, $-C(O)-(C_1-C_6 alkyl)$, and $-C(O)-O(C_1-C_6alkyl)$; and

10 R^{1A} , R^{1C} , and R^{1E} are optionally each independently selected from the group consisting of hydroxyl, halogen, $-C(O)-O-C_1-C_3alkyl$, $-C(O)-C_1-C_3alkyl$, methyl, and CF_3 ; and

Formula (A-VI) is:




wherein:

15 X' is $-O-P(O)(R^{41}R^{42})$, wherein R^{41} is selected from the group consisting of C_1 - C_6 alkyl, $-C_3$ - C_6 cycloalkyl, and $-OR^{43}$, wherein R^{43} is selected from the group consisting of H, C_1 - C_6 alkyl, $-C_3$ - C_6 cycloalkyl, phenyl and naphthyl; and R^{42} is selected from the group consisting of $-NH_2$, $-NH(C_1-C_6alkyl)$, and $-N(C_1-C_6alkyl)_2$, wherein the alkyl is optionally substituted by one, two or three substituents each independently selected from oxo, hydroxyl, halogen, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, $-C(O)-(C_1-C_6 alkyl)$, and $-C(O)-O(C_1-C_6alkyl)$; and

20

R^{1B} , R^{1C} , and R^{1D} are optionally each independently selected from the group consisting of hydroxyl, halogen, $-C(O)-O-C_1-C_3$ alkyl, $-C(O)-C_1-C_3$ alkyl, methyl, and CF_3 .


31. A method of ameliorating or treating a viral infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (A-Ia), or a pharmaceutically acceptable salt and/or a stereoisomer thereof, wherein
- 5 Formula (A-Ia):



wherein:

- X' is a halogen; and
- 10 one, two, three or four of R^{1A} , R^{1B} , R^{1C} , R^{1D} , and R^{1E} are optionally each independently selected from the group consisting of hydroxyl, halogen, $-C-O-C_1-C_3$ alkyl, $-C(O)-O-C_1-C_3$ alkyl, $-C(O)-C_1-C_3$ alkyl, methyl, and CF_3 .

32. A method of ameliorating or treating a viral infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (A-Ia-I), or a pharmaceutically acceptable salt and/or a stereoisomer thereof, wherein
- 15 Formula (A-Ia-I):



wherein:

5 X' is -O-P(O)(R⁴¹R⁴²), wherein R⁴¹ is selected from the group consisting of C₁-C₆alkyl, -C₃-C₆cycloalkyl, and -OR⁴³, wherein R⁴³ is selected from the group consisting of H, C₁-C₆alkyl, -C₃-C₆cycloalkyl, phenyl and naphthyl; and R⁴² is selected from the group consisting of -NH₂, -NH(C₁-C₆alkyl), and -N(C₁-C₆alkyl)₂, wherein the alkyl is
 10 optionally substituted by one, two or three substituents each independently selected from oxo, hydroxyl, halogen, C₃-C₆cycloalkyl, C₁-C₆alkoxy, -C(O)-(C₁-C₆ alkyl), and -C(O)-O(C₁-C₆alkyl); and
 one, two, three or four of R^{1A}, R^{1B}, R^{1C}, R^{1D}, and R^{1E} are optionally each independently selected from the group consisting of hydroxyl, halogen, -C-O-C₁-C₃alkyl, -C(O)-O-C₁-
 15 C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃.

33. The method of any one of claims 1-32, wherein the viral infection is from a virus selected from the group consisting of an RNA virus, a DNA virus, a coronavirus, a papillomavirus, a pneumovirus, a picornavirus, an influenza virus, an adenovirus, a cytomegalovirus, a polyomavirus, a poxvirus, a flavivirus, an alphavirus, an ebola virus, a
 15 morbillivirus, an enterovirus, an orthopneumovirus, a lentivirus, arenovirus, a herpes virus, and a hepatovirus.

34. The method of any one of claims 1-33, wherein the viral infection is a coronavirus infection.

35. A conjugate represented by:



wherein Cys₁₄₅ is cysteine at position 145 or equivalent active site cysteine on Mpro;

Z' is O, S or NH; and

VPI is a viral protease inhibitor.

36. A conjugate represented by:



wherein:


Cys₁₄₅ is cysteine at position 145 or equivalent active site cysteine on Mpro;

Z' is O, S or NH;

n is independently, for each occurrence, 0, 1 or 2; and

N* is a ring nitrogen of a compound, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, wherein N* comprises the compound, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, and the compound is a compound having Formula (A).

37. A conjugate represented by:




wherein Z' is O, S or NH; and

n is independently, for each occurrence, 0, 1 or 2.

38. The conjugate of claim 37, wherein Z' is O.

39. The conjugate of claim 37 or 38, wherein n is 1.

40. A conjugate represented by:




wherein Z' is O, S or NH;

n is independently, for each occurrence, 0, 1 or 2; and

one, two or three of R^{1A}, R^{1B}, R^{1C}, R^{1D}, and R^{1E} are optionally each independently selected from the group consisting of hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃.

41. A compound of Formula (A), or a pharmaceutically acceptable salt and/or a stereoisomer thereof, wherein Formula (A) is:



wherein:

5 X is NR²;

Z is O, S or NH;

R¹ is selected from the group consisting of H, C₁-C₆alkyl, phenyl, -C(O)R³¹, -C(S)R³¹, -C(NH)R³¹ and -C(O)OR³², wherein C₁-C₆ alkyl is optionally substituted by one, two or three substituents each independently selected from -C(O)NR^aR^b, -NR^aR^b, hydroxyl, S(O)_w-C₁-C₃alkyl, SH, phenyl and halogen; and phenyl, independently for each
10 occurrence, is optionally substituted by one, two or three substituents each independently selected from hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃;

R² is selected from the group consisting of -C(O)R³¹, -C(S)R³¹, -C(NH)R³¹ and -
15 C(O)OR³²;

R³ is selected from the group consisting of H, C₁-C₆alkyl, phenyl, -C(O)R³¹, -C(S)R³¹, -C(NH)R³¹ and -C(O)OR³², wherein C₁-C₆ alkyl is optionally substituted by one, two or three substituents each independently selected from -C(O)NR^aR^b, -NR^aR^b, hydroxyl, S(O)_w-C₁-C₃alkyl, SH, phenyl and halogen; and phenyl, independently for each
20 occurrence, is optionally substituted by one, two or three substituents each independently selected from hydroxyl, halogen, -C(O)-O-C₁-C₃alkyl, -C(O)-C₁-C₃alkyl, methyl, and CF₃;

R³¹ is C₁-C₆alkyl, wherein C₁-C₆ alkyl is substituted by one, two or three substituents each independently selected from hydroxyl, S(O)₂-C₁-C₃alkyl, halogen and
25 -O-P(O)(R⁴¹R⁴²);

R³² is C₁-C₆alkyl;

R⁴¹ is selected from the group consisting of C₁-C₆alkyl, -C₃-C₆cycloalkyl, and -OR⁴³, wherein R⁴³ is selected from the group consisting of H, C₁-C₆alkyl, -C₃-C₆cycloalkyl, phenyl and naphthyl;

5 R⁴² is selected from the group consisting of -NH₂, -NH(C₁-C₆alkyl), and -N(C₁-C₆alkyl)₂, wherein the C₁-C₆alkyl is optionally substituted by one, two or three substituents each independently selected from oxo, hydroxyl, halogen, C₃-C₆cycloalkyl, C₁-C₆alkoxy, -C(O)-(C₁-C₆ alkyl), and -C(O)-O(C₁-C₆alkyl);

10 R⁵ is independently selected for each occurrence from the group consisting of H, C₁-C₆alkyl, -C₁-C₃alkoxy, -S(O)_w-C₁-C₃alkyl, -NR^aR^b, cyano and halogen;

R⁷ is independently selected for each occurrence from the group consisting of H, C₁-C₆alkyl, phenyl and halogen;

15 R^a and R^b are each independently for each occurrence selected from the group consisting of H, C₁-C₃alkyl, and phenyl, or R^a and R^b taken together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring;

p is 2;

n is, for each occurrence, 1; and

w is independently, for each occurrence, 0, 1 or 2.

20 42. The compound of claim 41, wherein R¹ is C₁alkyl-phenyl, wherein phenyl is optionally substituted by one, two or three substituents each independently selected from hydroxyl, halogen, methyl, and CF₃